ইঙ্গিত ও ব্যবহার
VSIQQ এর জন্য নির্দেশিত:
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
প্রাপ্তবয়স্ক:
Neovascular (Wet) Age-Related Macular Degeneration (AMD): The recommended dose for BEOVU is 6 mg (0.05 mL of 120 mg/mL solution) monthly (approximately every 25-31 days) for the first three doses, followed by one dose of 6 mg (0.05 mL) every 8-12 weeks.Diabetic Macular Edema (DME): The recommended dose for BEOVU is 6 mg (0.05 mL of 120 mg/mL solution) every six weeks (approximately every 39-45 days) for the first five doses, followed by one dose of 6 mg (0.05 mL of 120 mg/mL solution) every 8-12 weeks.Pediatric Use: The safety and efficacy of BEOVU in pediatric patients has not been established.
পার্শ্বপ্রতিক্রিয়া
The most common adverse reactions reported in patients receiving VSIQQ are vision blurred, cataract, conjunctival hemorrhage, eye pain, and vitreous floaters.
সতর্কতা ও নিষেধাজ্ঞা
সতর্কতা ও সাবধানতা
Endophthalmitis and retinal detachment may occur following intravitreal injections. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay. Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported following BEOVU injections. Patients should be instructed to report any change in vision without delay. Increases in intraocular pressure (IOP) have been seen within 30 minutes of an intravitreal injection. There is a potential risk of arterial thromboembolic events (ATE) following intravitreal use of VEGF inhibitors
নিষেধাজ্ঞা
Ocular or Periocular Infections: Brolucizumab is contraindicated in patients with ocular or periocular infections.Active Intraocular Inflammation: Brolucizumab is contraindicated in patients with active intraocular inflammation.Hypersensitivity: Brolucizumab is contraindicated in patients with known hypersensitivity to brolucizumab or any of the excipients in Brolucizumab. Hypersensitivity reactions may manifest as rash, pruritus, urticaria, erythema, or severe intraocular inflammation.